Hopewell Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-09-17.
Hopewell Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 17, 2025. The filing reports $2.50M sold. Its industry group is Biotechnology. It names Thomas Hennessey, III (Director), Xutian Jing (Director), Nan Shen (Director) (SEC Form D, September 17, 2025).
Is this your company?
Sell to companies like Hopewell Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-17 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Hopewell Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Hopewell Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in September 2025, largest first.
Get an email when Hopewell Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Hopewell Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Hopewell Therapeutics, Inc. →Get the full cited report on Hopewell Therapeutics, Inc.
What the filing shows about Hopewell Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Hopewell Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Hopewell Therapeutics, Inc.'s address as 216 West Cummings Park, Woburn, MA 01801.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Hopewell Therapeutics, Inc. See pricing
Hopewell Therapeutics, Inc. is a registered filer with the SEC (CIK 1836562) and has filed since 2023-06-02. 3 filings are on record, the latest on 2025-09-17.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Hopewell Therapeutics, Inc.'s Form D of 2025-09-17 names Thomas Hennessey, III, Xutian Jing, Nan Shen and 3 more as its officers, directors or promoters.
Its new offerings report $5.50M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Thomas Hennessey, III is named as Director on the Form D that Hopewell Therapeutics, Inc. filed with the SEC on 17 September 2025, one of 6 people that filing names.
Xutian Jing is named as Director on the Form D that Hopewell Therapeutics, Inc. filed with the SEC on 17 September 2025, one of 6 people that filing names.
Nan Shen is named as Director on the Form D that Hopewell Therapeutics, Inc. filed with the SEC on 17 September 2025, one of 6 people that filing names.
Xiaowen Femg is named as Director on the Form D that Hopewell Therapeutics, Inc. filed with the SEC on 17 September 2025, one of 6 people that filing names.
Qiaobing Xu is named as Executive Officer and Director on the Form D that Hopewell Therapeutics, Inc. filed with the SEC on 17 September 2025, one of 6 people that filing names.
C. Paschall is named as Director on the Form D that Hopewell Therapeutics, Inc. filed with the SEC on 17 September 2025, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2025-09-17 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Hopewell Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Hopewell Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hopewell Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Hopewell Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Hopewell Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Hopewell Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/hopewell-therapeutics-inc-form-d-25000001